Program

The 1.5 day course consists of 10 invited lectures with ample time for Q&A, and breakout sessions. The preliminary agenda is as follows. The program is subject to change. Please stay tuned with us.

7 November
8:00 AMRegistration & Welcome coffee
8.20 AMOpening and introduction
8.30 AMThe clinical and economic importance of optimizing dose and schedule
Mark Ratain, The University of Chicago
9.30 AMPlacing preclinical drug metabolism and pharmacokinetic data in context
Magnus Ingelman-Sundberg, Karolinska Institutet
10:30 AMCoffee break
11.00 AMRedefining the primary objective of phase 1 trials
Ruth Plummer, Newcastle University
12.00 PMClinical endpoints useful for guiding early clinical development
Jaap Verweij, Erasmus Medical Centre
1.00 PMLunch & Breakout session slots
2.00 PMPharmacometrics for the non-pharmacometrician
Lena Friberg, Uppsala University
3.00 PMUsing genetic and pharmacokinetic data from early clinical trials to guide subsequent clinical development
Magnus Ingelman-Sundberg, Karolinska Institutet
4.00 PMCoffee break
4.30 PMOptimizing the use of pharmacodynamic biomarkers
Mark Ratain, The University of Chicago
5:30 PMEnd of Day 1
6.00 PMNetworking dinner (optional)
8 November
8.00 AMBreakfast & Breakout session slots
9.00 AMTrial designs for the development of combinations of an investigational drug and a marketed drug
Jaap Verweij, Erasmus Medical Centre
10.00 AMSpecial challenges for the development of immunotherapy drugs and combinations
Ruth Plummer, Newcastle University
11:00 AMCoffee break
11.30 AMUse of clinical trial simulation in oncology drug development
Lena Friberg, Uppsala University
12:30 PMClosure of the course

 

FACULTY